These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 21305523)
1. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Castelino FV; Seiders J; Bain G; Brooks SF; King CD; Swaney JS; Lorrain DS; Chun J; Luster AD; Tager AM Arthritis Rheum; 2011 May; 63(5):1405-15. PubMed ID: 21305523 [TBL] [Abstract][Full Text] [Related]
2. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin. Ohashi T; Yamamoto T Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255 [TBL] [Abstract][Full Text] [Related]
3. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis. Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295 [TBL] [Abstract][Full Text] [Related]
4. CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma. Vorstenbosch J; Al-Ajmi H; Winocour S; Trzeciak A; Lessard L; Philip A Arthritis Rheum; 2013 May; 65(5):1378-83. PubMed ID: 23436317 [TBL] [Abstract][Full Text] [Related]
5. A convenient method for producing the bleomycin-induced mouse model of scleroderma by weekly injections using a methylcellulose gel. Jun JB; Kim JK; Na YI; Jang SM; Paik SS; Kim YH Rheumatol Int; 2012 May; 32(5):1443-7. PubMed ID: 21448642 [TBL] [Abstract][Full Text] [Related]
6. The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model. Nakajima H; Nakajima K; Serada S; Fujimoto M; Naka T; Sano S Mod Rheumatol; 2021 Nov; 31(6):1120-1128. PubMed ID: 33535851 [TBL] [Abstract][Full Text] [Related]
7. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis. Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591 [TBL] [Abstract][Full Text] [Related]
8. Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. Ledein L; Léger B; Dees C; Beyer C; Distler A; Vettori S; Boukaiba R; Bidouard JP; Schaefer M; Pernerstorfer J; Ruetten H; Jagerschmidt A; Janiak P; Distler JHW; Distler O; Illiano S Br J Pharmacol; 2020 Sep; 177(18):4296-4309. PubMed ID: 32627178 [TBL] [Abstract][Full Text] [Related]
9. Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice. Akashi K; Saegusa J; Sendo S; Nishimura K; Okano T; Yagi K; Yanagisawa M; Emoto N; Morinobu A Arthritis Res Ther; 2016 May; 18(1):113. PubMed ID: 27209208 [TBL] [Abstract][Full Text] [Related]
10. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404 [TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice. Huang LS; Fu P; Patel P; Harijith A; Sun T; Zhao Y; Garcia JG; Chun J; Natarajan V Am J Respir Cell Mol Biol; 2013 Dec; 49(6):912-22. PubMed ID: 23808384 [TBL] [Abstract][Full Text] [Related]
12. Investigation of sensory neurogenic components in a bleomycin-induced scleroderma model using transient receptor potential vanilloid 1 receptor- and calcitonin gene-related peptide-knockout mice. Szabó A; Czirják L; Sándor Z; Helyes Z; László T; Elekes K; Czömpöly T; Starr A; Brain S; Szolcsányi J; Pintér E Arthritis Rheum; 2008 Jan; 58(1):292-301. PubMed ID: 18163477 [TBL] [Abstract][Full Text] [Related]
13. The Protective Effects of Bevacizumab in Bleomycin-Induced Experimental Scleroderma. Koca SS; Ozgen M; Dagli AF; Gozel N; Ozercan IH; Isik A Adv Clin Exp Med; 2016; 25(2):249-53. PubMed ID: 27627557 [TBL] [Abstract][Full Text] [Related]
14. The Role of TLR7 and TLR9 in the Pathogenesis of Systemic Sclerosis. Wang C; Oishi K; Kobayashi T; Fujii K; Horii M; Fushida N; Kitano T; Maeda S; Ikawa Y; Komuro A; Hamaguchi Y; Matsushita T Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892317 [TBL] [Abstract][Full Text] [Related]
15. Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F(2α) synthesis through adipose triglyceride lipase/calcium-independent phospholipase A(2). Kanno Y; Kawashita E; Kokado A; Okada K; Ueshima S; Matsuo O; Matsuno H Arthritis Rheum; 2013 Feb; 65(2):492-502. PubMed ID: 23124680 [TBL] [Abstract][Full Text] [Related]
16. Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Yamamoto T; Kuroda M; Nishioka K Arch Dermatol Res; 2000 Nov; 292(11):535-41. PubMed ID: 11194891 [TBL] [Abstract][Full Text] [Related]
17. Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis. Wu M; Pedroza M; Lafyatis R; George AT; Mayes MD; Assassi S; Tan FK; Brenner MB; Agarwal SK Arthritis Rheumatol; 2014 Apr; 66(4):1010-21. PubMed ID: 24757152 [TBL] [Abstract][Full Text] [Related]
18. mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. McCann MR; Monemdjou R; Ghassemi-Kakroodi P; Fahmi H; Perez G; Liu S; Shi-Wen X; Parapuram SK; Kojima F; Denton CP; Abraham DJ; Martel-Pelletier J; Crofford LJ; Leask A; Kapoor M Arthritis Res Ther; 2011; 13(1):R6. PubMed ID: 21266028 [TBL] [Abstract][Full Text] [Related]
19. Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma. Yang L; Serada S; Fujimoto M; Terao M; Kotobuki Y; Kitaba S; Matsui S; Kudo A; Naka T; Murota H; Katayama I PLoS One; 2012; 7(7):e41994. PubMed ID: 22911870 [TBL] [Abstract][Full Text] [Related]
20. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]